













Lrosthesis–patient mismatch in the mitral position: Old
oncept, new evidences
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Trevious studies have demonstrated that prosthesis–patient mismatch (PPM) is
associated with inferior hemodynamics, less regression of left ventricular
hypertrophy, more cardiac events, and higher mortality rates after aortic valve
eplacement.1-12 However, the hemodynamic and clinical impact of PPM after
itral valve replacement (MVR) are relatively unexplored.2,13-15 The elegant study
resented by Lam and colleagues16 in this issue of the Journal is indeed one of the
rst reports to demonstrate that PPM is associated with worse outcome after MVR.
he main findings of this study are that (1) the incidence of mitral PPM is much
igher than previously believed; (2) it is associated with a 4-fold increase in the risk
f congestive heart failure after MVR; and (3) it independently affects postoperative
urvival.
Mitral PPM is actually not a new concept. In the first report of mitral PPM
ublished in 1981, Rahimtoola and Murphy13 described the case of a patient who
emained symptomatic and had persistent pulmonary artery hypertension and pro-
ressive right-sided failure after MVR. In the early 1990s, Dumesnil and col-
eagues2,14 demonstrated the existence of a relationship between the indexed effec-
ive orifice area (EOA) and the transvalvular pressure gradient in normally
unctioning prostheses implanted in the mitral position. These findings are consis-
ent with the concept that PPM occurs when the EOA of the prosthesis is too small
n relation to the patient’s body size, resulting in an abnormally high postoperative
radient.1,17,18 In patients with an aortic prosthesis, previous studies consistently
ound a strong correlation between the indexed EOA and the postoperative
ransprosthetic gradients measured at rest or during exercise.1,17,19,20 However, as
rst reported by Dumesnil and colleagues in 1990,14 and confirmed by Li and
olleagues in 2005,15 the correlation between the indexed EOA and the mean
ransprosthetic pressure gradients is lower in patients with mitral prostheses (r 
.50) than in patients with aortic prostheses (r  0.75). In this context, it should be
mphasized that the hemodynamics of the mitral valve are more sensitive to the
hronotropic conditions than are those of the aortic valve and that these conditions
ay vary extensively from one patient to another. This difference may help explain
he lower correlation between indexed EOA and pressure gradients that is observed
n mitral prostheses. Subsequently, in a retrospective study of 56 patients who
nderwent MVR, we observed that the indexed mitral valve EOA correlated better
ith systolic pulmonary arterial pressure than with transprosthetic pressure gradi-
nts;15 this finding is consistent with the fact that pulmonary arterial pressure is
robably less influenced by chronotropic conditions than are pressure gradients. In
his study, we also found that mitral PPM is a frequent occurrence after MVR and
hat it is associated with persisting pulmonary hypertension.15 Given that pulmonary
ypertension may cause right-sided failure and is an important risk factor for
orbidity and mortality in patients with cardiovascular diseases, the next logical










































































































Ltep was to examine the association between mitral PPM
nd the occurrence of adverse events after MVR. In this
egard, the results of the study by Lam and colleagues16
rovide new compelling evidence that PPM is a powerful
ndependent risk factor for morbidity and mortality after
VR. Furthermore, these results are consistent with those
f another recent study from our laboratory showing that
itral PPM is independently associated with reduced sur-
ival after MVR.21
efinition of Prosthesis–Patient Mismatch in the
itral Position
here have been controversies in regard to the clinical
mpact of PPM in the aortic position, in large part because
he investigators used different parameters and criteria to
efine PPM. The parameter first proposed to identify PPM
as the indexed EOA.1,2 The EOA of the prosthesis can be
easured directly by Doppler echocardiography or “pro-
ected” from the normal reference values of EOA provided
n the literature for the different types and sizes of prosthe-
es. Some authors also attempted to characterize PPM in
erms of the indexed internal geometric orifice area (GOA)
ather than the indexed EOA.22-24 The GOA is a parameter
alculated from the static measurement of the internal di-
meter of the prosthesis stent. However, as opposed to the
easured or projected indexed EOA, the indexed GOA has
onsistently been shown to be unrelated to either postoper-
tive hemodynamics20,24,25 or outcomes8,11,22-24 after aortic
alve replacement. Similarly, we also recently reported that,
n patients with MVR, the indexed GOA grossly overesti-
ates the indexed EOA and in varying proportion depend-
ng on the type and size of prostheses.21 Furthermore, this
arameter was not significantly associated with postopera-
ive outcomes. Thus, it would seem that, as for the aortic
alve, the indexed EOA is the only valid parameter to
dentify PPM in the mitral position. In the majority of
atients included in the present study, the authors used the
rojected indexed EOA derived from reference EOA values
ublished in the literature to identify mitral PPM, and by
sing this parameter they found that PPM is independently
ssociated with worse outcome after MVR.16 However, in a
roportion of the patients included in this series, they used
he GOA of the prosthesis when the reference value of EOA
as not available. As acknowledged by the authors, this
ay have contributed to underestimating the prevalence of
PM in this series.
When the projected indexed EOA is used, it is important
o use reference values that are as reliable as possible. To
his effect, the values should be derived from large, prefer-
bly multicenter series with a sufficient number of patients
or each type and size of prostheses. This is, however, more
ifficult to achieve for mitral prostheses than for aortic
rostheses because there are less data available in the liter-
ture on the normal EOAs of mitral prostheses. Moreover, m
406 The Journal of Thoracic and Cardiovascular Surgery ● Junhe reference values should be derived from studies that
sed an appropriate method to measure the EOA. In this
egard, it has been shown that the pressure half-time method
s not valid to measure the EOA of mitral prostheses and
hat only the continuity equation method can be used for this
urpose.14,26,27 The pressure half-time method indeed over-
stimates the EOA of mitral prostheses and in varying
roportion depending on the chronotropic conditions and
he atrioventricular compliance. In the present article, the
uthors made no distinction between the EOAs derived
rom the pressure half time versus those derived from the
ontinuity equation,16 and this may have further contributed
o underestimate the prevalence of PPM in this series. Thus,
he reference values of EOA presented in the present article
hould not be taken at face value and will need to be further
alidated and updated.
In the aortic position, PPM is generally considered mild
r not clinically significant when the indexed EOA is
reater than 0.85 cm2/m2, moderate when it is equal to or
ess than 0.85 and greater than 0.65 cm2/m2, and severe
hen it is 0.65 cm2/m2 or less. Moderate PPM may be
revalent (20%-70%) in patients undergoing AVR, whereas
he prevalence of severe PPM ranges from 2% and 11%
epending on the series.17,18 Because of the lower pressure
egimen, the threshold values for mitral PPM are higher
han for aortic PPM. Mitral PPM is considered moderate
hen the indexed EOA is 1.2 to 1.3 cm2/m2 or less and
evere when it is 0.9 to 1.0 cm2/m2 or less.2,14-16,21 In the
resent study, the prevalence of PPM defined as an indexed
OA of 1.25 cm2/m2 or less was 32%. In our series, the
revalence of moderate PPM (indexed EOA  1.2 cm2/m2)
as 60% to 70% and of severe PPM (indexed EOA  0.9
m2/m2) was 5% to 10%.15,21 Thus, in light of these find-
ngs, it seems that PPM is a frequent occurrence not only in
he aortic position but also in the mitral position. The lower
revalence of PPM in the present series16 compared with
ur previous series15,21 may be related to the lower propor-
ion of smaller prostheses (27 mm) than in our series. As
utlined, the fact that Lam and colleagues16 used the GOA
r the EOA derived from the pressure half time to project
he postoperative indexed prosthetic valve area in a substan-
ial proportion of patients may also have contributed to
nderestimate the prevalence of PPM in their series.
oes Mitral Prosthesis–Patient Mismatch Matter?
PM in the aortic position is associated with less improve-
ent in symptoms and functional class,6 less regression of
eft ventricular hypertrophy,7 and more adverse cardiac
vents.4,8,10 Aortic PPM has a major impact on short-term
ortality,5,12 particularly if left ventricular dysfunction











































































































LFor a long time, mitral PPM remained unexplored and
ight have been thought to be a relatively rare phenomenon
ith minimal impact on postoperative outcomes. The com-
elling data presented by Lam and colleagues16 in this issue
f the Journal, however, demonstrate that this is not the
ase and that mitral PPM is not uncommon and is indepen-
ently associated with worse outcomes after MVR. In this
tudy, mitral PPM was indeed associated with a 4-fold
ncrease in the risk of recurrence of congestive heart failure
nd a 2.4-fold increase in the risk of mortality.16 This is
onsistent with the results of a recent study from our labo-
atory that included 929 consecutive patients undergoing
VR in whom PPM was associated with a 3-fold increase
n postoperative mortality after adjustment for other risk
actors.21 Furthermore, this association was maintained in
he subset of patients who underwent isolated MVR without
oncomitant coronary artery bypass grafting. The fact that 2
arge studies from 2 independent laboratories both demon-
trate that PPM is a strong independent risk factor for
ortality after MVR further supports the notion that mitral
PM does matter.
hy Does Mitral Prosthesis–Patient
ismatch Matter?
PM in the mitral position can be equated to residual mitral
tenosis with similar consequences, that is, the persistence
f abnormally high mitral gradients and increased left atrial
nd pulmonary arterial pressures. In turn, pulmonary arterial
ypertension may cause right-sided failure, and the persis-
ence of high left atrial pressures may predispose one to
trial fibrillation. This arrhythmia may compromise cardiac
utput and increase the incidence of thromboembolic com-
lications. The passive elevation in pulmonary capillary
ressure caused by the elevated left atrial pressure may also
ead to the development of pulmonary edema.
In the present study, PPM was not significantly associated
ith postoperative pulmonary hypertension, but smaller valve
ize and elevated transprosthetic gradients were. The lack of
ssociation between indexed EOA and pulmonary arterial
ressure is intriguing and in contrast with the results of other
tudies.15,21 The incomplete echocardiographic follow-up of
ulmonary arterial pressure and the use of GOA or EOA
erived from the pressure half time to estimate the indexed
OA in a certain number of cases may explain this result.
asuda and colleagues28 reported that the pulmonary arterial
ressure correlated with the transprosthetic gradient but not
ith the indexed prosthetic valve area. However, it should be
mphasized that these authors used the indexed GOA in lieu of
he indexed EOA to characterize prosthesis hemodynamic per-
ormance. As outlined, the indexed GOA is not a valid param-
ter to predict gradients or outcomes whether in the mitral or
he aortic position. Another possible explanation for these
pparent discrepancies is that a certain proportion of the pa-
ients with PPM were in a low output state and had a pseudo- q
The Journal of Thoracicormalization of gradients and pulmonary pressures, which in
urn could explain why PPM was more predictive of outcomes
han the latter variables.
revention of Mitral Prosthesis–Patient Mismatch:
n Important Challenge
revious studies demonstrated that the risk of PPM can be
redicted at the time of aortic valve replacement with the
se of the projected indexed EOA derived from normal
eference values. Some studies have also provided robust
vidence that the prevention of aortic PPM is feasible.25,29
hus, in light of these findings, it seems that there is a signif-
cant advantage to systematically calculate the projected in-
exed EOA of the prosthesis to be inserted at the time of
peration and in the case of anticipated PPM to consider
lternate procedures, such as aortic root enlargement or inser-
ion of a better-performing valve substitute such as supra-
nnular stented bioprostheses, stentless bioprostheses, newer-
eneration mechanical valves, homografts, or the Ross
peration. Moreover, most manufacturers now provide user-
riendly charts allowing easy calculation of the projected in-
exed EOA within the operating room.
The prevention of PPM in the mitral position represents
much greater challenge than in the aortic position. Indeed,
itral valve surgery does not allow annular enlargement,
nd the implantation of a homograft or a stentless prosthesis
s technically more demanding and associated with poor
ong-term durability. Thus, the only alternative at present is
he implantation of a prosthesis with a larger EOA for a
iven annulus size, which unfortunately may not be suffi-
ient to completely avoid PPM in some cases. In this sense,
he findings of the present study16 provide further impetus
or the development of better-performing mitral prostheses
nd alternative techniques allowing more frequent repair or
mplantation of better-performing prostheses. As opposed to
ortic prostheses, efforts to improve the hemodynamic per-
ormance of mitral prostheses have been more limited, but
comparison of existing prostheses nonetheless shows that
ize for size the type of prosthesis chosen may make a
ifference. Thus, these new compelling results16,21 should
urther encourage manufacturers to pursue their efforts in
his direction more intensively and to provide reliable EOA
eference values and user-friendly charts allowing easy cal-
ulation of the projected indexed EOA within the operating
oom.
Finally, it should be emphasized that the best way to
void PPM in the mitral position is to repair rather than to
eplace the valve, but this is unfortunately not possible in all
ases. Moreover, relatively unexplored but not excluded is
he fact that mitral valve annuloplasty, particularly if re-
trictive, might cause some degree of stenosis with conse-
uences similar to those observed with mitral PPM.
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